Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
Heng D, Xie W, Regan M, Warren M, Golshayan A, Sahi C, Eigl B, Ruether J, Cheng T, North S, Venner P, Knox J, N. K, Kollmannsberger C, McDermott D, Oh W, Atkins M, Bukowski R, Rini B, Choueiri T. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. Journal Of Clinical Oncology 2009, 27: 5794-5799. PMID: 19826129, DOI: 10.1200/jco.2008.21.4809.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBenzenesulfonatesBevacizumabCarcinoma, Renal CellFemaleHumansIndolesKidney NeoplasmsMaleMiddle AgedNiacinamidePhenylurea CompoundsPrognosisPyridinesPyrrolesSorafenibSunitinibSurvival RateVascular Endothelial Growth Factor AConceptsMetastatic renal cell carcinomaMemorial Sloan-Kettering Cancer CenterRenal cell carcinomaMedian OSAdverse prognostic factorOverall survivalPrognostic factorsVascular endothelial growth factorCell carcinomaMemorial Sloan-Kettering Cancer Center modelVascular endothelial growth factor-targeted agentGrowth factor-targeted agentsIndependent adverse prognostic factorTreated with vascular endothelial growth factorCancer CenterPredictor of shorter survivalFavorable-risk groupVEGF-targeted agentsPoor-risk groupTreated with sunitinibIntermediate-risk groupMedian Follow-UpCox proportional hazards regressionKarnofsky performance statusCanadian cancer centers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply